Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease

Tonelli, Marcello, Isles, Chris, Craven, Timothy, Tonkin, Andrew, Pfeffer, Marc A., Shepherd, James, Sacks, Frank M., Furberg, Curt, Cobbe, Stuart M., Simes, John, West, Malcolm, Packard, Chris, Curhan, Gary C.·2005·Circulation

Abstract

Background— Limited data suggest that HMG-CoA reductase inhibitors (statins) reduce rates of kidney function loss. We performed this analysis to determine whether pravastatin reduced the rate of kidney function loss over ≈5 years in people with or at high risk for coronary disease. Methods and Results— This was a post hoc subgroup analysis of data from 3 randomized double-blind controlled trials comparing pravastatin 40 mg/d and placebo in subjects with a previous acute coronary syndrome or who were at high cardiovascular risk. The primary outcome was the rate of change in estimated glomerular filtration rate (GFR; in mL/min per 1.73 m 2 /y). The Modified Diet and Renal Disease Study (MDRD) and Cockcroft-Gault equations were used to estimate GFR. We studied 18 569 participants, 3402 (18.3%) of whom had moderate chronic kidney disease as defined by an estimated GFR of 30 to 59.9 mL/min per 1.73 m 2 body surface area. In subjects with moderate chronic kidney disease at baseline, pravastatin reduced the adjusted rate of kidney function loss by ≈34%, although the absolute reduction in the rate of loss was small (0.22 mL/min per 1.73 m 2 /y by MDRD-GFR; 95% CI, 0.07 to 0.37). Pravastatin did not reduce the frequency of ≥25% decreases in kidney function in this group when MDRD-GFR was used to estimate GFR (relative risk [RR], 0.84; 95% CI, 0.66 to 1.06). When all 18 569 subjects were considered, pravastatin reduced the adjusted rate of kidney function loss by 8% (0.08 mL/min per 1.73 m 2 /y by MDRD-GFR; 95% CI, 0.01 to 0.15) and the risk of acute renal failure (RR, 0.60; 95% CI, 0.41 to 0.86) but did not significantly reduce the frequency of a ≥25% decline in kidney function by MDRD-GFR (RR, 0.94; 95% CI, 0.88 to 1.01). Conclusions— Pravastatin modestly reduced the rate of kidney function loss in people with or at risk for cardiovascular disease. However, the primary indication for the use of statins in people with or at risk for coronary events remains the reduction in mortality that results from their use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.104.517565

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 197

Metadata

Authors
Tonelli, M., Isles, C., Craven, T., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C., Cobbe, S. M., Simes, J., West, M., Packard, C., & Curhan, G. C.
Venue
Circulation
Published
2005-07-12
Volume
112
Issue
2
Pages
171-178
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2132627628
Cited by
197
References
6
FWCI
9.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease. https://app.cochat.ai/papers/10.1161/circulationaha.104.517565
The paper
Tonelli, M., Isles, C., Craven, T., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C., Cobbe, S. M., Simes, J., West, M., Packard, C., & Curhan, G. C. (2005). Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease. Circulation. https://doi.org/10.1161/circulationaha.104.517565

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.